These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38416633)

  • 61. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gender-related differences in pulmonary arterial hypertension targeted drugs administration.
    Marra AM; Benjamin N; Eichstaedt C; Salzano A; Arcopinto M; Gargani L; D Alto M; Argiento P; Falsetti L; Di Giosia P; Isidori AM; Ferrara F; Bossone E; Cittadini A; Grünig E
    Pharmacol Res; 2016 Dec; 114():103-109. PubMed ID: 27771466
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.
    Rose JA; Cleveland JM; Rao Y; Minai OA; Tonelli AR
    Chest; 2016 May; 149(5):1234-44. PubMed ID: 26836910
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacologic therapy for pulmonary artery hypertension.
    Nair A
    Curr Opin Cardiol; 2020 Nov; 35(6):643-656. PubMed ID: 32897888
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here?
    Macchia A; Mariani J; Comignani PD; Tognoni G
    Rev Recent Clin Trials; 2011 Sep; 6(3):228-34. PubMed ID: 21682677
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
    Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of rapid sequential combination therapy on distinct haemodynamic measures in newly diagnosed pulmonary arterial hypertension.
    Kramer T; Nattmann P; Gerhardt F; Stafiej P; Dumitrescu D; Ten Freyhaus H; Wißmüller M; Hohmann C; Baldus S; Rosenkranz S
    ESC Heart Fail; 2024 Jun; 11(3):1540-1552. PubMed ID: 38224960
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
    Gabler NB; French B; Strom BL; Liu Z; Palevsky HI; Taichman DB; Kawut SM; Halpern SD
    Chest; 2012 Jan; 141(1):20-26. PubMed ID: 21940766
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HIV-related pulmonary arterial hypertension: clinical presentation and management.
    Sitbon O
    AIDS; 2008 Sep; 22 Suppl 3():S55-62. PubMed ID: 18845923
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension.
    Skoro-Sajer N; Lang I
    Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1391-9. PubMed ID: 25363827
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 77. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
    BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery.
    De Wet CJ; Affleck DG; Jacobsohn E; Avidan MS; Tymkew H; Hill LL; Zanaboni PB; Moazami N; Smith JR
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1058-67. PubMed ID: 15052203
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Budev MM; Minai OA; Arroliga AC
    Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.